A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

Davide Melisi,Antoine Hollebecque,Do-Youn Oh,Emiliano Calvo,Anna M. Varghese,Erkut Borazanci,Teresa Macarulla Mercade,Francesca Simionato,Joon Oh Park,Johanna C. Bendell,Sandrine Faivre,Yumin Zhao,Ivelina Gueorguieva,Michael Man,Shawn T. Estrem,Karim A. Benhadji,M Lanasa,Susan C. Guba,Rocio Garcia-Carbonero

A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

2019

Davide Melisi
Antoine Hollebecque
Do-Youn Oh
Emiliano Calvo
Anna M. Varghese
Erkut Borazanci
Teresa Macarulla Mercade
Francesca Simionato
Joon Oh Park
Johanna C. Bendell
Sandrine Faivre
Yumin Zhao
Ivelina Gueorguieva
Michael Man
Shawn T. Estrem
Karim A. Benhadji
M Lanasa
Susan C. Guba
Rocio Garcia-Carbonero

4124Background: Pancreatic cancer (PC) is characterized by a highly immunosuppressive microenvironment, and immune checkpoint inhibitors as monotherapy have been ineffective to date. TGFβ is common...

Keywords:

PD-L1
Durvalumab
Cohort
Antibody
Pathology
Kinase
Cancer research
Galunisertib
Receptor
Transforming growth factor
Medicine
anti pd 1
Pancreatic cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations